| Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, DT Yeung, ... Blood, The Journal of the American Society of Hematology 122 (4), 515-522, 2013 | 849 | 2013 |
| Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure TP Hughes, MJ Mauro, JE Cortes, H Minami, D Rea, DJ DeAngelo, ... New England Journal of Medicine 381 (24), 2315-2326, 2019 | 359 | 2019 |
| Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline S Branford, DT Yeung, WT Parker, ND Roberts, L Purins, JA Braley, ... Blood, The Journal of the American Society of Hematology 124 (4), 511-518, 2014 | 224 | 2014 |
| Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML S Branford, DT Yeung, DM Ross, JA Prime, CR Field, HK Altamura, ... Blood, The Journal of the American Society of Hematology 121 (19), 3818-3824, 2013 | 222 | 2013 |
| Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose … AJC Bloor, A Patel, JE Griffin, MH Gilleece, R Radia, DT Yeung, D Drier, ... Nature medicine 26 (11), 1720-1725, 2020 | 213 | 2020 |
| Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease S Branford, P Wang, DT Yeung, D Thomson, A Purins, C Wadham, ... Blood, The Journal of the American Society of Hematology 132 (9), 948-961, 2018 | 182 | 2018 |
| TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets DT Yeung, MP Osborn, DL White, S Branford, J Braley, A Herschtal, ... Blood, The Journal of the American Society of Hematology 125 (6), 915-923, 2015 | 108 | 2015 |
| Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells DM Ross, IS Pagani, N Shanmuganathan, CH Kok, JF Seymour, AK Mills, ... Leukemia 32 (12), 2572-2579, 2018 | 78 | 2018 |
| The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib WT Parker, DTO Yeung, AL Yeoman, HK Altamura, BA Jamison, CR Field, ... Blood, The Journal of the American Society of Hematology 127 (15), 1870-1880, 2016 | 73 | 2016 |
| The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment LN Eadie, P Dang, VA Saunders, DT Yeung, MP Osborn, AP Grigg, ... Leukemia 31 (1), 75-82, 2017 | 69 | 2017 |
| Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells YD Irani, A Hughes, J Clarson, CH Kok, N Shanmuganathan, DL White, ... British Journal of Haematology 191 (3), 433-441, 2020 | 63 | 2020 |
| TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy E Nievergall, J Reynolds, CH Kok, DB Watkins, M Biondo, SJ Busfield, ... Leukemia 30 (6), 1263-1272, 2016 | 62 | 2016 |
| Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia N Shanmuganathan, IS Pagani, DM Ross, S Park, ASM Yong, JA Braley, ... Blood, The Journal of the American Society of Hematology 137 (9), 1196-1207, 2021 | 61 | 2021 |
| High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment SL Heatley, T Sadras, CH Kok, E Nievergall, K Quek, P Dang, B McClure, ... Haematologica 102 (12), e490, 2017 | 60 | 2017 |
| BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management S Branford, DT Yeung, JA Prime, SY Choi, J Bang, JE Park, DW Kim, ... Blood, The Journal of the American Society of Hematology 119 (18), 4264-4271, 2012 | 58 | 2012 |
| Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes CE Chong, P Venugopal, PH Stokes, YK Lee, PJ Brautigan, DTO Yeung, ... Leukemia 32 (1), 194-202, 2018 | 56 | 2018 |
| Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission IS Pagani, P Dang, VA Saunders, R Grose, N Shanmuganathan, CH Kok, ... Leukemia 34 (4), 1052-1061, 2020 | 44 | 2020 |
| KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease MO Forgione, BJ McClure, LN Eadie, DT Yeung, DL White Cancer letters 469, 410-418, 2020 | 42 | 2020 |
| Consumer engagement in health care policy, research and services: A systematic review and meta-analysis of methods and effects LK Wiles, D Kay, JA Luker, A Worley, J Austin, A Ball, A Bevan, M Cousins, ... PloS one 17 (1), e0261808, 2022 | 40 | 2022 |
| The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia LC Fox, KD Cummins, B Costello, D Yeung, R Cleary, C Forsyth, ... Blood advances 1 (13), 802-811, 2017 | 38 | 2017 |
